Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 95475939ADM2001 | Other Identifier | Janssen Research & Development, LLC | |
| 2024-517814-13-00 | Registry Identifier | EUCT number |
Not provided
Not provided
Terminated: futility criteria met at interim efficacy analysis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A: Dupilumab | Active Comparator | Participants will receive Dupilumab dose regimen 1 subcutaneously through Week 22. |
|
| Group B: JNJ-95475939 | Experimental | Participants will receive JNJ-95475939 dose regimen 1 subcutaneously through Week 22. |
|
| Group C: JNJ-95475939 | Experimental | Participants will receive JNJ-95475939 dose regimen 2 subcutaneously through Week 22. |
|
| Group D: JNJ-95475939 | Experimental | Participants will receive JNJ-95475939 dose regimen 3 subcutaneously through Week 22. |
|
| Group E: Placebo | Placebo Comparator | Participants will receive matching placebo subcutaneously through Week 10, then switch to receive JNJ-95475939 dose regimen 1 subcutaneously between Week 12 and Week 22. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dupilumab | Drug | Dupilumab will be administered subcutaneously. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants with Eczema Area and Severity Index (EASI) 75 Response at Week 12 | EASI-75 response is defined as at least 75 percent (%) improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 12 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With EASI-90 Response at Week 12 | EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. |
Not provided
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| First OC Dermatology | Fountain Valley | California | 92708 | United States | ||
| University of California Los Angeles - Division of Dermatology |
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| JNJ-95475939 |
| Drug |
JNJ-95475939 will be administered subcutaneously. |
|
| Placebo | Drug | Placebo will be administered subcutaneously. |
|
| Baseline, Week 12 |
| Percentage of Participants With EASI-100 Response at Week 12 | EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 12 |
| Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of 0 or 1 and a Reduction From Baseline of Greater Than Equal to (>=) 2 Points at Week 12 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 12 |
| Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 12 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 12 |
| Percent Change From Baseline in the EASI Total Score at Week 12 | The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 12 |
| Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 12 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 12 |
| Percent Change from Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 12 | The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 12 |
| Percent Change from Baseline in Skin Pain NRS Score at Week 12 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 12 |
| Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 12 | The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times. | Baseline, Week 12 |
| Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 12 | The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | From Baseline through Week 12 |
| Percentage of Participants with EASI-75 Response at Week 16 | EASI-75 response is defined as at least 75% improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 16 |
| Percentage of Participants with EASI-90 Response at Week 16 | EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 16 |
| Percentage of Participants with EASI-100 Response at Week 16 | EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score was used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Week 16 |
| Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 16 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 16 |
| Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 16 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 16 |
| Percent Change from Baseline in the EASI Total Score at Week 16 | The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 16 |
| Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain Numerical Rating Scale (NRS) Score From Baseline to Week 16 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 16 |
| Percent Change from Baseline in PP-NRS Score at Week 16 | The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 16 |
| Percent Change from Baseline in Skin Pain NRS Score at Week 16 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 16 |
| Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 16 | The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times. | Baseline, Week 16 |
| Percentage of Participants Achieving a >= 4-Point Reduction in PP-NRS Score From Baseline Through Week 24 | The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | From Baseline Through Week 24 |
| Percentage of Participants with EASI-75 Response at Week 24 | EASI-75 response is defined as at least 75% improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 24 |
| Percentage of Participants with EASI-90 Response at Week 24 | EASI-90 response is defined as at least 90% improvement in EASI total score. EASI-90 response is defined as at least 90% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Week 24 |
| Percentage of Participants with EASI-100 Response at Week 24 | EASI-100 response is defined as at least 100% improvement in EASI total score. EASI-100 response is defined as at least 100% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Week 24 |
| Percentage of Participants Achieving vIGA-AD Score of 0 or 1 and a Reduction From Baseline of >= 2 Points at Week 24 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 24 |
| Percentage of Participants Achieving vIGA-AD Score of 0 and a Reduction From Baseline of >= 2 Points at Week 24 | vIGA-AD is an assessment instrument used in clinical studies to rate the severity of AD, based on a 5-point scale ranging from 0, where 0=Clear: No inflammatory signs of AD; 1=almost clear: Barely perceptible erythema, induration/papulation and/or lichenification; 2=mild: Slight but definite erythema, induration/papulation and/or minimal lichenification. No oozing or crusting; 3=moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present and 4=severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present. Higher scores are indicative of a more severe AD. | Baseline, Week 24 |
| Percent Change from Baseline in the EASI Total Score at Week 24 | The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI score is used to measure the severity and extent of AD and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting a higher severity of AD. | Baseline, Week 24 |
| Percentage of Participants Achieving a >= 4-Point Reduction in Skin Pain NRS Score From Baseline to Week 24 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 24 |
| Percent Change From Baseline in PP-NRS Score at Week 24 | The PP-NRS is a single item asking participants to assess their worst itch over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 24 |
| Percent Change from Baseline in Skin Pain NRS Score at Week 24 | The Skin Pain NRS is a single item asking participants to assess their worst skin pain over the past 24 hours. The response categories range from 0 (no pain) to 10 (worst pain). Higher scores indicating greater severity. | Baseline, Week 24 |
| Percent Change from Baseline in the Score of Item 2 of the AD Sleep Scale at Week 24 | The AD sleep scale is a validated 3-item PRO instrument to capture self-reported impact of itch on sleep disturbance each day, including difficulty falling asleep, number of night-time awakenings, and difficulty falling back asleep after waking during the previous night. Each AD Sleep Scale item is scored individually. For Item 2, participants select the number of times they woke up each night, ranging from 0 to 29 times. | Baseline, Week 24 |
| Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Participants with AEs and SAEs will be reported. An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs are AEs with onset during the intervention phase or that are a consequence of a preexisting condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability or incapacity; congenital anomaly. | From Baseline up to Week 36 |
| Los Angeles |
| California |
| 90024 |
| United States |
| Hamilton Research LLC | Alpharetta | Georgia | 30022 | United States |
| DeNova Research | Chicago | Illinois | 60602 | United States |
| Dawes Fretzin Clinical Research Group LLC | Indianapolis | Indiana | 46250 | United States |
| Indiana Clinical Trial Center | Plainfield | Indiana | 46168 | United States |
| Red River Research Partners LLC | Fargo | North Dakota | 58103 | United States |
| Optima Research | Boardman | Ohio | 44512 | United States |
| Oregon Medical Research Center | Portland | Oregon | 97201 | United States |
| Arlington Center for Dermatology | Arlington | Texas | 76011 | United States |
| Center for Clinical Studies | Houston | Texas | 77004 | United States |
| Progressive Clinical Research | San Antonio | Texas | 78213 | United States |
| Frontier Derm Partners CRO, LLC | Mill Creek | Washington | 98012 | United States |
| CIPREC | Buenos Aires | C1061AAS | Argentina |
| INAER - Investigacion en Alergias y Enfermedades Respiratorias | Buenos Aires | C1425 | Argentina |
| Instituto de Neumonologia y Dermatologia | Buenos Aires | C1425 | Argentina |
| Derma Internacional S A | Buenos Aires | C1426 | Argentina |
| Ceti - Centro de Estudos Em Terapias Inovadoras | Curitiba | 80.030-110 | Brazil |
| Hospital De Clinicas De Porto Alegre | Porto Alegre | 90035 903 | Brazil |
| Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP | Ribeirão Preto | 14048 900 | Brazil |
| Instituto Brasil de Pesquisa Clinica | Rio de Janeiro | 20241 180 | Brazil |
| Fundacao do ABC Centro Universitario FMABC | Santo André | 09060 870 | Brazil |
| BR TRIALS Ensaios Clinicos e Consultoria Ltda | São Paulo | 01236030 | Brazil |
| Dermatology Research Institute Inc | Calgary | Alberta | T2J 7E1 | Canada |
| Dr. Chih ho Hong Medical | Surrey | British Columbia | V3R 6A7 | Canada |
| Karma Clinical Trials Inc. | St. John's | Newfoundland and Labrador | A1A 4Y3 | Canada |
| SimcoDerm Medical and Surgical Dermatology Centre | Barrie | Ontario | L4M 7G1 | Canada |
| Lynderm Research Inc. | Markham | Ontario | L3P 1X2 | Canada |
| Innovaderm Research Inc. | Montreal | Quebec | H2X 2V1 | Canada |
| Centre De Recherche Dermatologique Du Quebec Metropolitain | Québec | Quebec | G1V 4X7 | Canada |
| Fachklinik Bad Bentheim | Bad Bentheim | 48455 | Germany |
| Charite - Universitaetsmedizin Berlin (CCM) | Berlin | 10117 | Germany |
| ISA - Interdisciplinary Study Association GmbH | Berlin | 10789 | Germany |
| Studienzentrum an der Hase GbR | Bramsche | 49565 | Germany |
| Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden | Dresden | 01307 | Germany |
| Universitatsklinikum Dusseldorf | Düsseldorf | 40225 | Germany |
| Universitatsklinikum Frankfurt | Frankfurt | 60596 | Germany |
| Eurofins bioskin GmbH | Hamburg | 20095 | Germany |
| Studienzentrum Dr Schwarz Germany | Langenau | 89129 | Germany |
| Fukuoka University Hospital | Fukuoka | 814-0180 | Japan |
| Osaka Habikino Medical Center | Habikino | 583 8588 | Japan |
| Teikyo University Hospital | Itabashi Ku | 173 8606 | Japan |
| Kume Clinic | Sakai | 593 8324 | Japan |
| Sapporo Skin Clinic | Sapporo | 060 0063 | Japan |
| Jitaikai Tachikawa dermatology clinic | Tachikawa | 190 0023 | Japan |
| Shirasaki Dermatology Clinic | Takaoka Shi | 933-0871 | Japan |
| Mie University Hospital | Tsu | 514-8507 | Japan |
| Queens Square Medical Facilities | Yokohama | 220 6208 | Japan |
| Nomura Dermatology Clinic | Yokohama | 221 0825 | Japan |
| Centrum Badan Klinicznych PI House sp z o o | Gdansk | 80 546 | Poland |
| Care Clinic | Katowice | 40 568 | Poland |
| Centrum Medyczne Angelius Provita | Katowice | 40-611 | Poland |
| Centrum Medyczne All Med | Krakow | 30 033 | Poland |
| Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna | Krakow | 30-002 | Poland |
| Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna | Lodz | 90-338 | Poland |
| Therapia Nova | Warsaw | 01 595 | Poland |
| Klinika Ambroziak Dermatologia | Warsaw | 02 953 | Poland |
| Royalderm Agnieszka Nawrocka | Warsaw | 02962 | Poland |
| WroMedica I Bielicka A Strzalkowska s c | Wroclaw | 51 685 | Poland |
| Hosp. Gral. Univ. Dr. Balmis | Alicante | 03010 | Spain |
| Hosp. Univ. San Cecilio | Granada | 18016 | Spain |
| Hosp. Univ. de Bellvitge | LHospitalet de Llobregat | 08907 | Spain |
| Grupo Dermatologico Y Estetico Pedro Jaen | Madrid | 28002 | Spain |
| Hosp. Univ. de La Princesa | Madrid | 28006 | Spain |
| Hosp. de Manises | Manises | 46940 | Spain |
| Hosp. Clinico Univ. de Santiago | Santiago de Compostela | 15706 | Spain |
| The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust | Kings Lynn | PE30 4ET | United Kingdom |
| Royal London Hospital | London | E1 1BB | United Kingdom |
| Northwick Park Hospital | London | HA13UJ | United Kingdom |
| Guys and St Thomas NHS Foundation Trust | London | SE1 9RT | United Kingdom |
| Salford Royal Hospital | Salford | M6 8HD | United Kingdom |
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C582203 | dupilumab |
Not provided
Not provided
Not provided